Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ALDX

ALDX - Aldeyra Therapeutics Inc Stock Price, Fair Value and News

3.54USD+0.19 (+5.67%)Market Closed
Watchlist

Market Summary

USD3.54+0.19
Market Closed
5.67%

ALDX Stock Price

View Fullscreen

ALDX RSI Chart

ALDX Valuation

Market Cap

208.2M

Price/Earnings (Trailing)

-4.56

EV/EBITDA

-0.84

Price/Free Cashflow

-4.95

MarketCap/EBT

-3.24

ALDX Price/Sales (Trailing)

ALDX Profitability

Return on Equity

-37.15%

Return on Assets

-31.02%

Free Cashflow Yield

-20.2%

ALDX Fundamentals

ALDX Earnings

Earnings (TTM)

-45.7M

Earnings Growth (Yr)

43.75%

Earnings Growth (Qtr)

8.9%

Breaking Down ALDX Revenue

Last 7 days

8.8%

Last 30 days

11.8%

Last 90 days

26.0%

Trailing 12 Months

-43.2%

How does ALDX drawdown profile look like?

ALDX Financial Health

Current Ratio

6.81

Debt/Equity

0.02

Debt/Cashflow

-15.83

ALDX Investor Care

Shares Dilution (1Y)

0.45%

Diluted EPS (TTM)

-0.24

Tracking the Latest Insider Buys and Sells of Aldeyra Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 07, 2023
phillips gary m.
acquired
3,001
0.552
5,437
-
Sep 07, 2023
brady todd c
acquired
150,728
0.552
273,058
president and ceo
Sep 07, 2023
brady todd c
sold (taxes)
-532,887
7.22
-73,807
president and ceo
Aug 22, 2023
walker neal
acquired
5,301
0.552
9,604
-
Jun 27, 2023
bronstein ben
acquired
5,301
0.552
9,604
-
Feb 28, 2023
brady todd c
acquired
-
-
238,750
president and ceo
Aug 10, 2022
perceptive advisors llc
bought
117,750
7.85
15,000
-
Aug 09, 2022
perceptive advisors llc
bought
750,000
7.5
100,000
-
Aug 08, 2022
perceptive advisors llc
bought
702,280
7.24
97,000
-
Aug 05, 2022
perceptive advisors llc
bought
979,950
6.95
141,000
-

1–10 of 50

Which funds bought or sold ALDX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
12.37
-109,000
158,000
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
added
1,005
490,000
592,000
0.05%
Feb 15, 2024
Legal & General Group Plc
reduced
-75.16
-218,482
32,784
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
10,548
10,548
-%
Feb 15, 2024
Virtus ETF Advisers LLC
sold off
-100
-63,193
-
-%
Feb 15, 2024
JANE STREET GROUP, LLC
reduced
-48.41
-644,825
239,827
-%
Feb 15, 2024
Palo Alto Investors LP
added
40.21
-282,762
791,382
0.07%
Feb 15, 2024
BARCLAYS PLC
reduced
-53.83
-700,000
224,000
-%
Feb 14, 2024
Providence Wealth Advisors, LLC
new
-
336,361
336,361
0.30%
Feb 14, 2024
J. Goldman & Co LP
sold off
-100
-180,360
-
-%

1–10 of 45

Are Funds Buying or Selling ALDX?

Are funds buying ALDX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALDX
No. of Funds

Unveiling Aldeyra Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
perceptive advisors llc
14.6%
8,593,586
SC 13G/A
Feb 13, 2024
vanguard group inc
6.68%
3,927,597
SC 13G
Jan 29, 2024
blackrock inc.
5.8%
3,430,774
SC 13G
Oct 19, 2023
perceptive advisors llc
14.7%
8,593,586
SC 13G/A
Oct 04, 2023
knoll capital management, llc
6.1%
3,595,916
SC 13G
Feb 14, 2023
perceptive advisors llc
19.4%
11,350,085
SC 13G/A
Feb 03, 2023
state street corp
0.30%
173,281
SC 13G/A
Jul 08, 2022
blackrock inc.
1.7%
974,947
SC 13G
Feb 14, 2022
perceptive advisors llc
17.0%
9,903,879
SC 13G/A
Feb 09, 2022
state street corp
5.31%
3,082,352
SC 13G

Recent SEC filings of Aldeyra Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G
Major Ownership Report
Feb 13, 2024
8-K
Current Report
Jan 29, 2024
SC 13G
Major Ownership Report
Jan 04, 2024
8-K
Current Report
Dec 21, 2023
8-K
Current Report
Dec 19, 2023
8-K
Current Report
Nov 28, 2023
8-K
Current Report

Peers (Alternatives to Aldeyra Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Aldeyra Therapeutics Inc News

Latest updates
Yahoo Finance24 hours ago

Aldeyra Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-5.4%14715616818119020122323324725614783.0088.0072.0063.0076.0077.0074.0088.0095.0037.00
  Current Assets-5.3%14715516818118920122223324725614783.0088.0071.0063.0075.0077.0073.0087.0095.0037.00
    Cash Equivalents-5.5%14315216514412912115923024125013878.0086.0061.0039.0044.0052.0039.0044.0047.0018.00
  Net PPE-20.5%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Liabilities-5.7%24.0026.0031.0030.0027.0027.0032.0027.0028.0023.0021.0024.0019.0019.0020.0027.0027.007.0010.008.009.00
  Current Liabilities38.5%22.0016.0016.0015.0024.0016.0016.0012.0012.007.0011.0012.006.005.005.0013.0012.006.009.008.008.00
  Long Term Debt-73.8%3.0010.0015.0015.003.0011.0016.0016.0015.0015.0010.0011.0013.0014.0015.0015.0014.00---1.00
    LT Debt, Current128.4%13.006.001.001.00----------------0.00
    LT Debt, Non Current-73.8%3.0010.0015.0015.003.0011.0016.0016.0015.0015.0010.0011.0013.0014.0015.0015.0014.00---1.00
Shareholder's Equity-5.3%12313013715116217419120622023412660.0069.0053.0043.0048.0051.0067.0078.0087.0029.00
  Retained Earnings-2.1%-389-381-372-356-343-329-311-294-278-263-248-236-225-216-209-199-186-167-154-138-127
  Additional Paid-In Capital0.3%512511510508506504502500499497374296295270253247237235233225156
Shares Outstanding0.7%59.0059.0059.0059.0058.0058.0058.0058.0058.0054.0046.0039.00---------
Float------228---649---128---153---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations39.9%-8,024-13,357-9,443-11,231-12,574-19,958-12,873-11,577-8,434-9,072-13,471-8,317-6,237-7,579-15,359-11,226-8,315-12,810-12,631-7,968-7,688
  Share Based Compensation-49.8%7891,5744,1902,8212,2371,2941,9379841,4182,3242,3821,6301,7571,7421,9541,9492,1532,0951,8861,0181,274
Cashflow From Investing---30,00027,00019,016-17,938-58,031----7.81-5,50017,3006,224-4,2855,6767,9229,164-28,972-21.30
Cashflow From Financing-6066.7%-3155.0053.00-1,197-23.00-64.00120,36974,0641*26,22412,4253,2538,33314,844-9.1440866,2891,113

ALDX Income Statement

2023-09-30
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:    
Research and development$ 6,961,669$ 11,539,620$ 25,160,437$ 38,344,594
General and administrative2,588,7013,244,93611,535,86810,638,602
Loss from operations(9,550,370)(14,784,556)(36,696,305)(48,983,196)
Other income (expense):    
Interest income1,902,242648,2425,463,9281,094,001
Interest expense(538,743)(416,917)(1,557,171)(1,233,279)
Total other income (expense), net1,363,499231,3253,906,757(139,278)
Net loss$ (8,186,871)$ (14,553,231)$ (32,789,548)$ (49,122,474)
Earnings Per Share, Basic$ (0.14)$ (0.25)$ (0.56)$ (0.84)
Earnings Per Share, Diluted$ (0.14)$ (0.25)$ (0.56)$ (0.84)
Weighted Average Number of Shares Outstanding, Basic58,990,18958,457,86358,858,63158,352,991
Weighted Average Number of Shares Outstanding, Diluted58,990,18958,457,86358,858,63158,352,991

ALDX Balance Sheet

2023-09-30
Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 143,334,888$ 144,419,364
Marketable securities029,881,520
Prepaid expenses and other current assets3,875,1266,722,229
Total current assets147,210,014181,023,113
Right-of-use assets64,459249,265
Fixed assets, net7,77419,279
Total assets147,282,247181,291,657
Current liabilities:  
Accounts payable247,194133,625
Accrued expenses7,843,38914,065,885
Current portion of long-term debt13,461,108911,763
Operating lease liabilities65,628249,265
Total current liabilities21,617,31915,360,538
Long-term debt, net of current portion2,657,18914,923,090
Total liabilities24,274,50830,283,628
Commitments and contingencies (Note14)
Stockholders' equity:  
Preferred stock, $0.001 par value, 15,000,000 shares authorized none issued and outstanding00
Common stock, $0.001 par value; 150,000,000 authorized and 59,187,326 and 58,560,078 shares issued and outstanding, respectively59,18758,560
Additional paid-in capital512,454,738507,770,045
Accumulated other comprehensive loss0(103,938)
Accumulated deficit(389,506,186)(356,716,638)
Total stockholders, equity123,007,739151,008,029
Total liabilities and stockholders’ equity$ 147,282,247$ 181,291,657
ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
 CEO
 WEBSITEwww.aldeyra.com
 EMPLOYEES15

Aldeyra Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Aldeyra Therapeutics Inc? What does ALDX stand for in stocks?

ALDX is the stock ticker symbol of Aldeyra Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aldeyra Therapeutics Inc (ALDX)?

As of Thu Feb 22 2024, market cap of Aldeyra Therapeutics Inc is 208.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALDX stock?

You can check ALDX's fair value in chart for subscribers.

What is the fair value of ALDX stock?

You can check ALDX's fair value in chart for subscribers. The fair value of Aldeyra Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aldeyra Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aldeyra Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ALDX is over valued or under valued. Whether Aldeyra Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aldeyra Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALDX.